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Background: The BH3-only members of the Bcl-2 protein family have been proposed to play a key role in the
control of apoptosis and in the initiation of the apoptotic pathways. In this study, we evaluated the expression of
Bim, Noxa, and Puma in non-small cell lung cancer (NSCLC).
Methods: A total of 135 surgically resected NSCLCs were immunohistochemically assessed for Bim, Noxa, and
Puma expression. The immunoscores were determined, and then its correlation with either the clinicopathological
variables or the survival outcomes were analyzed.
Results: Immunohistochemical reactivity for Bim, Noxa, and Puma was detected in the cytoplasm of the tumor
cells. Bim expression was associated with several clinicopathological factors, including sex (p< 0.001), smoking habit
(p = 0.03), pathological histology (p = 0.001), pathological T stage (p = 0.03), pathological disease stage (p = 0.02), and
differentiation of tumor (p< 0.001). Multivariate logistic regression analysis showed a significant correlation between
low Bim expression and squamous cell carcinoma (p = 0.04), in addition to a correlation between high Bim
expression and well differentiated tumors (p = 0.02). Analysis of cellular biological expression demonstrated a link
between low Bim expression and high Ki67. While Noxa expression was also shown to be correlated with both
smoking habit (p = 0.02) and the pathological histology (p = 0.03), there was no strong association observed
between the expression and the clinical features when they were examined by a multivariate logistic regression
analysis. No correlations were noted between Puma expression and any of the variables. Our analyses also indicated
that the expression levels of the BH3-only proteins were not pertinent to the survival outcome.
Conclusions: The current analyses demonstrated that Bim expression in the NSCLCs was associated with both
squamous cell carcinoma histology and tumor proliferation.Introduction
Lung cancer is the most common cause of malignancy-
related death in the world, and despite advances in both
detection and treatment, its incidence rate is still in-
creasing. Although the development of several new
agents and molecular targeted therapies has led to an
increased survival of patients with non-small cell lung
cancer (NSCLC), the actual cure rates remain low for
advanced NSCLC patients [1, 2]. In order to improve
the poor prognosis of patients with NSCLC, further
studies that specifically examine the clinical features of* Correspondence: konishj@med.hokudai.ac.jp
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distribution, and reproduction in any mediumlung cancer in addition to the development of new
therapeutic strategies will be required.
Deregulation of apoptosis has been demonstrated to
lead to cancer development, proliferation, and treatment
resistance [3, 4]. The mitochondria-mediated apoptotic
pathway is largely regulated by the Bcl-2 family proteins
[5], with members of this family possessing at least one of
four conserved motifs that are known as the Bcl-2 hom-
ology domains (BH1 to BH4). These domains have been
divided into three subfamilies, with the BH3-only proteins,
such as Bik, Bid, Bim, Bmf, Hrk, Bad, Noxa, and Puma,
exhibiting sequence homology only in BH3 [5-7]. Bim is
induced by the withdrawal of growth factors via either of
the two major epidermal growth factor receptor (EGFR)-
dependent pathways: the Raf/MAPK or the Akt/PI3K [8,
9]. Noxa and Puma are transcriptional targets of p53 anded Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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apoptosis [10, 11]. Recent studies have also demonstrated
that aberrations of the BH3-only proteins are linked to
tumorigenesis in several cancers [12, 13]. Furthermore,
there has been an accumulation of evidence showing an
association between the frequent loss of BH3-only pro-
teins and a poor cancer prognosis [14-16]. Although pre-
vious data have demonstrated the expression of Bcl-2
family proteins in lung cancer [17, 18], there has been very
little information available on the actual role that these
proteins might play in lung cancer, and thus, further stud-
ies are warranted.
In the current study, we used immunohistochemistry
to examine the expression of Bim, Noxa and Puma in a
series of NSCLCs. Subsequently, we attempted to deter-
mine if there were any correlations between the expres-
sion of these proteins and features such as clinical and
clinicopathological parameters, cell biological character-
istics, or survival outcomes.
Materials and Methods
Patient and Specimens This study was approved by the
Medical Ethics Committee of Hokkaido University School
of Medicine. A total of 135 patients (91 males and 44
females) who underwent radical surgery between 1982
and 1994 at Hokkaido University Medical Hospital were
included in the study. Informed consent was obtained
from all patients prior to enrollment in the study. Histo-
logical diagnoses and grades of differentiation of the pri-
mary tumor specimens were determined in accordance
with the 1982 World Health Organization criteria. These
histological analyses demonstrated that 74 samples were
adenocarcinoma (Ad), 54 were squamous cell carcinoma
(Sq), 5 were adenosquamous cell carcinoma (AS), and 2
were large cell carcinoma (La). For the statistical analyses,
tumor specimens were divided into either a Sq or non-Sq
group, which included the Ad, AS, and La. The patho-
logical stage (pStage) was based on the guidelines of the
American Joint Committee on Cancer for post-operative
tumor-lymph node-metastasis (TNM) classification [19].
Immunohistochemistry Immunohistochemical analyses
were performed for Bim, Noxa, Puma, or Bcl-2 using
4 μm-thick histological sections that were cut from
formalin-fixed, paraffin-embedded blocks. After the sec-
tions were deparaffinized in xylene and then rehydrated
in ethanol, the sections were treated in 10 mM citrate
buffer, pH 6.0 for 20 minutes at 121°C in an autoclave in
order to retrieve the antigenicity. To block the endogen-
ous peroxidase activity, the sections were subsequently
immersed in methanol containing 1.5 % hydrogen perox-
ide for 20 minutes followed by incubation with normal
rabbit serum in order to block the nonspecific antibodybinding sites. Sections were incubated at 4°C overnight
with either anti-Bim/Bod rabbit polyclonal antibody
(Sigma-Aldrich corp. St Louis, MO, USA), diluted 1:300,
primary anti-Noxa rabbit polyclonal antibody (Biovision,
Inc., Mountain View, CA, USA), diluted 1:200, primary
anti-Puma rabbit polyclonal antibody (ab27669, Abcam,
Cambridge, MA, USA), diluted 1:50, or primary anti-
Bcl-2 mouse monoclonal antibody (clone124, DAKO,
Tokyo, JAPAN), diluted 1:40. Immunostaining was per-
formed by using the biotin-streptavidin immunoperoxi-
dase method with 3,3-diaminobenzidine as the
chromogen (SAB-PO kit; Nichirei, Tokyo, Japan).
Hematoxylin solution was used for counterstaining. For
each batch of sample that was stained, one sample that
was positive for either Bim, Noxa, Puma, or Bcl-2 was
included as a positive external control. Using a BX 40
microscope (Olympus, Tokyo, Japan), the immunohisto-
chemical evaluations were assessed twice by a single in-
vestigator (J.S.K.) who was blinded to the status of the
other immunohistological and clinical data.
Immunohistochemical Scoring Bim, Noxa, and Puma
staining levels were classified as either high or low, as
per a previously described method [17, 18]. To be
defined as having a high expression of Bim, Noxa or
Puma, moderate-to-strong staining intensity had to be
observed in more than 50 % of the tumor cells. Samples
were scored as low when the expression was present in
less than 50 % of the tumor cells. Immunohistochemi-
cally staining sections were judged high expression for
Bcl-2 expression when more than 10 % of cancer cells
showed cytoplasmic staining [20, 21].
Western Blot Analysis Cell lysates of Jurkat cells, the
NSCLC cell line (HCC2429), and tumor tissues were
prepared by lysing cells and tissues in radioimmune pre-
cipitation assay buffer (150 mM NaCl; 1 % Triton X-100;
1 % B deoxycholate; 0.1 % sodium dodecyl sulfate (SDS);
10 mM Tris, pH 7.4) supplemented with 100 μg/mL leu-
peptin, 100 μg/mL aprotinin, and 10 mM phenylmethyl-
sulfonyl fluoride. Protein samples were resolved using
SDS-PAGE gels, transferred onto nitrocellulose mem-
branes (Amersham Biosciences Inc., St. Albans, United
Kingdom), and then incubated with the primary antibody
overnight. Subsequently, the membrane was incubated
with anti-rabbit antibody conjugated with horseradish per-
oxidase (NA934V, Amersham Biosciences Inc.) and devel-
oped using the Amersham ECL system. Cell lysates of the
Jurkat cells were used as the positive controls for Bim and
Noxa [22]. In a prior study, we demonstrated that there is
expression of Puma in the HCC2429 cell line [23].
Statistical Analysis The association between Bim,
Noxa, or Puma and the categorical variables were
Figure 1 Western blot analysis and immunohistochemistry of the surgical specimens obtained from three patients in the current
cohort. In the Western blot analysis, Bim was strongly detected in Cases 1 and 3, while Noxa was moderately found in Case 2, and Puma was
strongly detected in Case 3. These findings match the results of the immunohistochemical staining analyses. Cell lysates of the Jurkat cells (J)
were used as positive controls for Bim and Noxa. HCC2429 (H) was used as the positive control for Puma.
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appropriate. When assessing the effects of more than
one factor on Bim or Noxa expression, we performed a
multivariate logistic regression analysis. Survival
curves were estimated using the Kaplan-MeierFigure 2 Bim immunohistochemical staining pattern. The immunohisto
and adenocarcinoma (Ad) samples.method, with differences in the survival distributions
then evaluated using the log-rank test. The level of sig-
nificance was set at p< 0.05. Statistical analyses were
done using StatView 5.0.1 (SAS Institute Inc., Cary,
NC, USA).chemical pattern for Bim in both the squamous cell carcinoma (Sq)
Figure 3 Noxa immunohistochemical staining pattern. The immunohistochemical pattern for Noxa in both the squamous cell carcinoma (Sq)
and adenocarcinoma (Ad) samples.
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Expression of Bim, Noxa, and Puma
The quality of the antibodies that were used in this study
was first tested by Western blot analysis and immunohis-
tochemistry using diverse cell lines and surgical speci-
mens. Cell lysates of Jurkat cells were used as positive
controls for Bim and Noxa [22]. In addition, we previously
showed that there is expression of Puma in the NSCLC
cell line, HCC2429 [23]. The expression of Bim, Noxa and
Puma noted during the Western blot and immunohisto-
chemistry analyses is seen in Figure 1. In three surgical
specimens that were obtained from the study cohort of
NSCLC, Bim was strongly detected in Cases 1 and 3, while
Noxa was moderately found in Case 2, and Puma was
strongly detected in Case 3. These data were consistent
with the results of our immunohistochemical staining,Figure 4 Puma immunohistochemical staining pattern. The immunohi
(Sq) and adenocarcinoma (Ad) samples.with the staining for all of the antibodies observed within
the cytoplasm of the cells (Figures 2, 3 and 4). Bim showed
homogenous staining within tumors. Noxa and Puma
showed focal and heterogeneous staining within tumors.
Normal bronchial epithelial cells, which were used as the
internal positive control, showed moderate to strong ex-
pression of all BH3-only proteins. No expression of these
proteins was noted in the normal alveolar pneumocytes.
Correlation between the expression of the BH3-only
proteins and the clinicopathological variables
We evaluated the relationship between Bim, Noxa, or
Puma expression and the clinicopathological variables.
High Bim expression was observed in 58 patients with
NSCLC (43 %). This expression was shown to be asso-
ciated with sex (p< 0.001), smoking habit (p = 0.03),stochemical pattern for Puma in both the squamous cell carcinoma
Table 1 Correlation between Bim expression and the
clinicopathological characteristics of 135 resected
Non-small cell lung cancers
No. of Patients
Characteristics low high p
Age
<65 38 27 0.74
≥65 39 31
Sex
Men 61 30 <0.001
Women 16 28
Smoker
Never 16 22 0.03
Smoker 61 36
Histology




T1 16 22 0.03
T2-4 61 36
pN3
N0 47 44 0.09
N1-3 30 14
pStage4
I 41 42 0.02
II-IV 36 16
Differentiation
Moderate/Poor 64 29 <0.001
Well 13 29
1Other: adenosquamous cell carcinoma and large cell carcinoma.
2pT: pathological tumor classifications.
3pN: pathological nodal classifications.
4pStage: pathological disease stage.
Table 2 Correlation between Noxa expression and the
clinicopathological characteristics of 135 resected
Non-small cell lung cancers
No. of Patients
Characteristics low high p
Age
<65 39 26 0.22
≥65 49 21
Sex
Men 63 28 0.16
Women 25 19
Smoker
Never 19 19 0.02
Smoker 69 28
Histology




T1 22 16 0.28
T2-4 66 31
pN3
N0 61 30 0.46
N1-3 27 17
pStage4
I 55 28 0.74
II-IV 33 19
Differentiation
Moderate/Poor 64 29 0.19
Well 24 18
1Other: adenosquamous cell carcinoma and large cell carcinoma.
2pT: pathological tumor classifications.
3pN: pathological nodal classifications.
4pStage: pathological disease stage.
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(p = 0.03), pathological disease stage (p = 0.02), and dif-
ferentiation of tumor (Table 1). High Noxa expression
was detected in 47 NSCLCs (35 %), with the expression
linked to both smoking habit (p = 0.02) and pathological
histology (p = 0.03) (Table 2). Although a high Puma ex-
pression was seen in 59 patients with NSCLC (44 %),
this expression had no influence on any of the variables
(Table 3). Multivariate logistic regression analysis used to
examine the correlation between Bim expression and the
clinicopathological variables demonstrated significant
associations between both the low Bim expression and Sq
histology (p= 0.04) and the high Bim expression with well
differentiated tumors (p= 0.02) (Table 4). No link was
observed between Noxa expression and either smoking
habit or pathological histology in the multivariate logisticregression analysis (Table 5). When we further analyzed
the relationship between BH3-only proteins and patient
survival, we found that the expression of these BH3-only
proteins was not correlated with the survival outcomes of
any of the subgroups analyzed, including both the disease
stage and the histological type.
Correlation between BH3-only proteins and cellular
biological expression
Results of previous studies on the expression of p27, Ki67
and cyclin E have implied that there is a prognostic signifi-
cance for these expressions [24, 25]. Therefore, using the
same study cohort, we tested the correlation between the
BH3-only proteins and these cellular biological expres-
sions. Our results showed that a high Ki67 expression level
was associated with a low Bim expression (p< 0.01),
Table 3 Correlation between Puma expression and the
clinicopathologic characteristics of 135 resected
Non-small cell lung cancers
No. of Patients
Characteristics low high p
Age
<65 34 31 0.81
≥65 42 28
Sex
Men 51 40 0.93
Women 25 19
Smoker
Never 21 17 0.88
Smoker 55 42
Histology




T1 23 15 0.50
T2-4 53 44
pN3
N0 49 42 0.47
N1-3 27 17
pStage4
I 42 41 0.09
II-IV 34 18
Differentiation
Moderate/Poor 53 40 0.81
Well 23 19
1Other: adenosquamous cell carcinoma and large cell carcinoma.
2pT: pathological tumor classifications.
3pN: pathological nodal classifications.
4pStage: pathological disease stage.
Table 5 Multivariate Logistic Regression Analysis for the





Smoker (Smoker vs Never1) 0.49 (0.21-1.11) 0.09
Histology (Sq2 vs Non-Sq3) 0.63 (0.28-1.38) 0.25
*OR: odds ratio, **95%CI: 95% confidence interval.
1Never: never smoker.
2Sq: Squamous cell carcinoma.
3Non-Sq: Included adenocarcinoma, adenosquamous and large cell carcinoma.
Table 4 Multivariate Logistic Regression Analysis for the





Sex (Men vs Women) 0.32 (0.09-1.17) 0.08
Smoker (Smoker vs Never1) 0.46 (0.30-1.80) 0.50
Histology (Sq2 vs Non-Sq3) 0.37 (0.17-0.84) 0.04
pT4 (pT2-4 vs pT1) 0.77 (0.34-1.97) 0.65
pStage5 (II-IV vs I) 0.47 (0.33-1.83) 0.12
Differentiation (Well vs Moderate/Poor) 5.12 (1.16-6.92) 0.02
*OR: odds ratio, **95%CI: 95% confidence interval.
1Never: never smoker.
2Sq: squamous cell carcinoma.
3Non-Sq: Included adenocarcinoma, adenosquamous and large cell carcinoma.
4pT: pathologic tumor classification.
5pStage: pathologic disease stage.
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or Noxa expression and any of the tested cellular
biological expressions (Table 6). We also examined the
correlation between the expression of Bcl-2 protein and
BH3-only proteins, because the viability of cells is deter-
mined by the balance of expression of pro-apoptotic pro-
teins such as BH3-only proteins and the expression of
anti-apoptotic Bcl-2 family members,. However, there was
no statistical correlation between Bcl-2 expression and
BH3-only proteins. It suggests that other anti-apoptotic
Bcl-2 proteins/BH3-only proteins axis may be involved in
this study. Moreover, other survival pathway like MAPK
or AKT/PI3K pathway may contribute to the cell viability.
Discussion
In the current study, we examined the expressions of the
BH3-only proteins, Bim, Noxa and Puma, and found
that there was a correlation between these expressions
and the clinicopathological features. While we also
found that low Bim expression was significantly more
prevalent in the Sq histology versus non-Sq histologu,
this study revealed no significant correlations betweenTable 6 Correlation between Bim, Noxa or Puma
expression and cellular biological expression
Bim Noxa Puma
low high p low high p low high p
No. of Patients No. of Patients No. of Patients
Ki67
High 56 28 <0.01 59 25 0.11 51 33 0.18
Low 21 30 29 22 25 26
p27
High 71 50 0.52 79 42 0.95 68 53 0.95
Low 6 8 9 5 8 6
CyclinE
High 45 29 0.33 49 25 0.78 45 29 0.24
Low 32 29 39 22 31 30
Bcl-2
High 32 25 0.97 37 20 0.95 37 20 0.51
Low 45 33 51 27 39 39
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or Puma. Although there has been one pilot study that
used immunohistochemistry to examine the expression
of the BH3-only proteins, Bad, Bid and Bim, in NSCLC
samples [17], the current study is the first to clarify the
frequency of Bim, Noxa and Puma in a large series of
NSCLCs.
In another study of NSCLCs that reported a similar
pattern, the results showed that while a loss of Bim was
observed in 2 out of 22 samples in the Sq histology and
in 0 out of 19 in the Ad histology, the loss was not sta-
tistically significant [17]. Although many promising
treatments have been recently developed for adenocar-
cinoma of the lung, including EGFR-TKI (tyrosine kinase
inhibitor) and pemetrexed [1, 26], there are few optimal
treatments that can be used for Sq. However, our results
suggest the possibility that the loss of Bim expression in
Sq might be related to resistance to these anticancer
drugs.
Bim has previously been shown to have a role in
tumor suppression [12, 13]. This is supported by our
current data that showed a significant association be-
tween the loss of Bim expression and a high Ki67
expression, which is a marker of tumor proliferation. In
addition, high Bim expression was correlated with well
differentiated tumors. Taken together, this suggests that
Bim may have an impact on both cell proliferation activ-
ity and tumor feature in NSCLC.
Bim has also been shown to be required for initiation of
the apoptosis induced by EGFR-TKI in NSCLC cell lines
with EGFR-TKI-sensitive mutations [27–29]. Furthermore,
inhibition of Bim induction has also been observed in
NSCLC with the EGFR-TKI resistance mutation, T790M,
which suggests that Bim induction leads to the active re-
sponse of the EGFR-TKI treatment [28]. Recently, BH3-
mimetics have been developed and shown to have cytotoxic
effects on many solid tumors [30, 31]. The BH3-mimetic,
ABT-737, along with its oral analogue, AB7-263, have espe-
cially been shown to promote apoptosis and suppress
tumor growth in small-cell lung cancer [32]. Although it
has been observed that several NSCLC cell lines show rela-
tive resistance to ABT-737 monotherapy [33, 34], ABT-737
significantly enhanced EGFR-TKI-induced cell killing of
NSCLC, and thus, this combined treatment might be a
promising new therapy [29]. Although we have not exam-
ined the correlation between Bim expression and responses
to treatment, our current data suggest that Bim expression
might be involved with tumor proliferation and feature,
which supports the notion that Bim expression could be a
useful therapeutic marker.
Noxa and Puma expression levels have been investigated
in various cancers, including colon cancer and ameloblas-
tic tumors, and were shown not to have any clinical
significance [35–37]. This is consistent with our currentdata. To the best of our knowledge, there has been little
data reported concerning the relationship between these
two BH3-only proteins and the various clinicopathological
factors in NSCLC. Unlike Bim expression, these two pro-
teins may have not been implicated in the pathogenesis of
NSCLC, which suggests that further investigations of their
roles are warranted.
Our findings also did not find any impact of the exam-
ined BH3-only proteins on survival outcomes. Likewise,
there have been no other reports on any relationships
between these proteins and patient prognosis in NSCLC.
However, it has been verified that both Bim and Puma
expression are independent prognostic factors in colon
cancer [14]. Conversely, Bim expression has not been
previously linked with patient prognosis in either gastric
cancer or malignant mesothelioma [15, 38]. Therefore,
the origin and stage (early or advanced) of the tumor in
addition to the subsequent therapies that have been used
against the disease might account for the prognosis dis-
crepancies that have been described. Moreover, these
proteins are known to be regulated by many different
complex upstream pathways, such as AKT/PI3K, MAPK,
or p53 [8–11]. Thus, the various levels of pathway regu-
lation that could potentially exist might also be contrib-
uting factors for the differences noted in the prognosis
between the different types of malignant diseases.
Conclusions
The current findings demonstrated that the loss of Bim
expression was associated with both Sq histology and
tumor aggressiveness in NSCLC.
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